VANCOUVER, BC and CONSHOHOCKEN, PA, April 10 /PRNewswire/ - Neuromed Pharmaceuticals, a biopharmaceutical company developing next-generation chronic pain drugs, today announced the appointment of Dr. Stephen Arneric to its executive team. Dr. Arneric will be Vice President of Research and Preclinical Development responsible for the oversight of the Neuromed's discovery and preclinical operations.
Dr. Arneric was most recently a Senior Director and Head for Central Nervous Systems Biology at Pfizer, Ann Arbor Laboratories. Prior to that he held senior positions with Pharmacia Corporation, DuPont Pharmaceuticals and Abbott Laboratories. Dr. Arneric has extensive leadership and management experience as well as expertise in the areas of neurology, urology, pain and psychiatry.
"We are delighted to add the expertise of Dr. Arneric to the Neuromed team. His experience and track record managing large teams and programs will be an asset as Neuromed grows as a pharmaceutical company and collaborates with Merck to recognize the significant potential value of developing breakthrough medicines for pain and other neurological disorders," said Dr. Christopher Gallen, President and CEO, Neuromed.
Dr. Arneric received his PhD in Pharmacology from the University of Iowa. Following postdoctoral training at Cornell University Medical College, Dr. Arneric accepted an Assistant Professor position in the Department of Neurology at Cornell and Department of Pharmacology at Southern Illinois University School of Medicine. Dr. Arneric continues to serve as Adjunct Professor at Southern Illinois University School of Medicine.
About Neuromed Pharmaceuticals
Neuromed is a privately held biopharmaceutical company developing the next generation of chronic pain drugs with pipeline programs in anxiety, epilepsy and cardiovascular disease such as hypertension. Located in Vancouver, Canada and Conshohocken, USA, the Company's drug development programs are designed around validated clinical targets associated with large unmet markets. Neuromed exclusively focuses on calcium channels as drug targets and is the first company to take an orally available drug selectively targeting neuronal calcium channels into human clinical trials. For more information visit www.neuromed.com
/NOTE TO PHOTO EDITORS: A photo accompanying this release is available on the CNW Photo Network and archived at http://photos.newswire.ca. Additional archived images are also available on the CNW Photo Archive website at http://photos.newswire.ca. Images are free to accredited members of the media/ For more information regarding this press release, contact: Communications contact in Canada Catherine Ducharme Neuromed Pharmaceuticals Ltd. Cell: (604) 813-6104 Phone: (604) 909-2547 Email: cducharme@neuromed.com Communications contact in the US Matt Dallas Financial Dynamics Business Communications Phone: (212) 850-5627 Cell: (917) 363-1333 Email: mdallas@fd-us.com
Neuromed Pharmaceuticals Ltd.CONTACT: For more information regarding this press release, contact:Communications contact in Canada: Catherine Ducharme, NeuromedPharmaceuticals Ltd., Cell: (604) 813-6104, Phone: (604) 909-2547, Email:cducharme@neuromed.com; Communications contact in the US: Matt Dallas,Financial Dynamics, Business Communications, Phone: (212) 850-5627, Cell:(917) 363-1333, Email: mdallas@fd-us.com
